Job J C
Ann Endocrinol (Paris). 1986;47(5):372-7.
The availability of large supplies of synthetic human growth hormone (hGH) and somatocrinin (GRF) may lead to new therapeutic possibilities, however still hypothetical. This review briefly summarizes the main data previously acquired with extracted hGH in medical practice: clinical pharmacology, long-term results in completely GH-deficient children, short-term results in partial or atypical GH deficiency and in some other types of severe growth retardation. The data reported up to now (July 1986) from clinical trials using synthetic hGHs and GRF are preliminary. However they allow to discuss guidelines for the new trials, unavoidably long and accurately designed, which are needed for extending and delineating the clinical use of new human growth hormones.
大量合成人生长激素（hGH）和生长激素释放因子（GRF）的可得性可能会带来新的治疗可能性，不过目前仍只是假设。本综述简要总结了此前在医学实践中使用提取的hGH所获得的主要数据：临床药理学、完全生长激素缺乏儿童的长期结果、部分或非典型生长激素缺乏以及其他一些严重生长迟缓类型的短期结果。截至目前（1986年7月），使用合成hGH和GRF的临床试验所报告的数据都是初步的。然而，这些数据有助于讨论新试验的指导原则，新试验不可避免地需要长时间且精心设计，这对于扩展和明确新型人生长激素的临床应用是必要的。
